A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms KEYNOTE-017
- Sponsors Merck & Co
- 05 Jun 2018 Results including data from an expansion cohort (n=24; as of 21 Jun 2017), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 According to a Merck & Co media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
- 19 Jan 2018 Planned primary completion date changed from 20 Jan 2018 to 6 Feb 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History